Clinical Trial Update: A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study of CP-724,714 for HER2-overexpressing metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CP-724,714

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: TERMINATED